



#19/B

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 30 2003

TECH CENTER 1600/2000

IN RE APPLICATION OF
McKearn et al.
Attorney's Docket 3167/5Z/US
FILED: October 5, 2001

) SERIAL NO. 09/857,995
) GROUP ART UNIT: 1624
) EXAMINER: Sudhaker B. Patel
) DATE: April 25, 2003

TITLE: METHOD OF USING MMP INHIBITORS AND ONE OR MORE
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN
THE TREATMENT OF NEOPLASIA

AMENDMENT B

The official letter dated November 25, 2002 (Paper number 18), having a shortened statutory period for response of three (3) months, expiring February 25, 2003, has been received, and in response thereto the following Amendment B is respectfully submitted. A request for continued examination (RCE) is filed with this response.

It is requested that the requirements under 37 CFR 1.121 be waived according to the Notice of February 25, 2003 (Official Gazette of the USPTO, Vol. 1267 Number 4) titled "Amendments in a Revised Format Now Permitted."